Please use this identifier to cite or link to this item:
|Title:||Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2).|
|Authors:||Barlow, A. D.|
Moore, C. E.
Campbell, S. C.
Shaw, J. A.
Nicholson, M. L.
Herbert, T. P.
|Publisher:||Springer Verlag (Germany)|
|Citation:||Diabetologia, 2012, 55 (5), pp. 1355-1365|
|Abstract:||Rapamycin (sirolimus) is one of the primary immunosuppressants for islet transplantation. Yet there is evidence that the long-term treatment of islet-transplant patients with rapamycin may be responsible for subsequent loss of islet graft function and viability. Therefore, the primary objective of this study was to elucidate the molecular mechanism of rapamycin toxicity in beta cells.|
|Rights:||Copyright The Author(s) 2012. This article is published with open access at Springerlink.com. This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.|
|Description:||The online version of this article (doi:10.1007/s00125-012-2475-7) contains peer-reviewed but unedited supplementary material, which is available to authorised users.|
|Appears in Collections:||Published Articles, Dept. of Infection, Immunity and Inflammation|
Files in This Item:
|art%3A10.1007%2Fs00125-012-2475-7.pdf||Publisher version||469.58 kB||Adobe PDF||View/Open|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.